Investor Relations :: BioSig Technologies, Inc. (BSGM)

Investor Relations

BioSig Technologies, Inc BSGM issues a shareholder letter

April 17, 2020

View Shareholder Letter

View Telebriefing Transcript

ViralClear adds St. David's HealthCare in Austin, Texas, to its Planned Phase II trial for its Broad-Spectrum Oral Anti-Viral Candidate for COVID-19

June 5, 2020

View All News

Conference Call on Upcoming and Recent Developments for Phase II Human Clinical Trials of its Broad-Spectrum Oral Anti-viral Candidate for Treatment of COVID-19

Jun 9, 2020 • 11:00am EDT

View All Events

Q1 2020

Quarter Ended Mar 31, 2020

PDF HTML

ZIP XLS HTML

XBRL

Latest Report

Latest Annual Report

View Annual Report

Symbol

Nasdaq: BSGM

Price

Change

Volume

52 week Low/High

Day Low/High

BioSig Technologies is a medical device company developing a proprietary technology platform designed to improve the $4 billion electrophysiology (EP) marketplace.

Investor Presentation

Investor Relations

T: (203) 409-5444 x 133
info@biosigtech.com

Transfer Agent

Action Stock Transfer
Justeene Blankenship
2469 E. Fort Union Blvd
Suite 214
Salt Lake City, UT 84121
T: (801) 274-1088
action@actionstocktransfer.com
www.actionstocktransfer.com